- Home
- AMTM vs NUVL Comparison
AMTM vs NUVL Comparison
Compare AMTM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTM
- NUVL
- Stock Information
- Founded
- AMTM 2020
- NUVL 2017
- Country
- AMTM United States
- NUVL United States
- Employees
- AMTM N/A
- NUVL N/A
- Industry
- AMTM
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- AMTM
- NUVL Health Care
- Exchange
- AMTM NYSE
- NUVL Nasdaq
- Market Cap
- AMTM 5.6B
- NUVL 5.4B
- IPO Year
- AMTM N/A
- NUVL 2021
- Fundamental
- Price
- AMTM $24.21
- NUVL $80.48
- Analyst Decision
- AMTM Buy
- NUVL Strong Buy
- Analyst Count
- AMTM 6
- NUVL 10
- Target Price
- AMTM $25.50
- NUVL $119.60
- AVG Volume (30 Days)
- AMTM 2.2M
- NUVL 582.7K
- Earning Date
- AMTM 08-05-2025
- NUVL 08-07-2025
- Dividend Yield
- AMTM N/A
- NUVL N/A
- EPS Growth
- AMTM N/A
- NUVL N/A
- EPS
- AMTM 0.10
- NUVL N/A
- Revenue
- AMTM $11,261,000,000.00
- NUVL N/A
- Revenue This Year
- AMTM $70.67
- NUVL N/A
- Revenue Next Year
- AMTM $2.35
- NUVL N/A
- P/E Ratio
- AMTM $253.45
- NUVL N/A
- Revenue Growth
- AMTM 38.56
- NUVL N/A
- 52 Week Low
- AMTM $16.01
- NUVL $55.54
- 52 Week High
- AMTM $34.50
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- AMTM N/A
- NUVL 59.85
- Support Level
- AMTM N/A
- NUVL $76.27
- Resistance Level
- AMTM N/A
- NUVL $80.90
- Average True Range (ATR)
- AMTM 0.00
- NUVL 2.55
- MACD
- AMTM 0.00
- NUVL 0.19
- Stochastic Oscillator
- AMTM 0.00
- NUVL 81.61
About AMTM AMENTUM HOLDINGS INC
Amentum Holdings Inc is engaged in engineering and technology solutions. The United States and its allies trust it to address their technical and complex scientific, security, and sustainability challenges.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.